Search by

Scorpius BioManufacturing

brand-profile-thumb

Company Headquarters

1305 East Houston Street , San Antonio, TX, 78205, US

Driving Directions Phone: View Phone

Company Description

Scorpius BioManufacturing is a U.S. biologics CDMO providing cGMP manufacturing, bioanalytical, and process development services for mammalian and microbial programs. Scorpius specializes in working with start-ups and emerging biotechs, giving small-volume programs the attention and flexibility they deserve.

Request more information from Scorpius BioManufacturing

Content From Scorpius BioManufacturing

Sponsored Content

The Bioanalytical Development Journey

As the number of new companies in biopharma continues to grow, so does their demand for outsourcing at every level of biopharmaceutical development.

Released By Scorpius BioManufacturing

Sponsored Content

A CDMO’s Mission To Empower Emerging Biotechs

A global pandemic magnified the need for more biologics manufacturing capacity. Capacity, however, isn’t the whole story.

Released By Scorpius BioManufacturing

Sponsored Content

Does Your Biologics CDMO Truly Have A Culture Of Quality?

What is a culture of quality, and how do you know if a biologics CDMO can earnestly make this claim?

Released By Scorpius BioManufacturing

Sponsored Content

ABC: Analytics For Biomanufacturing

Samir Lakhashe, Director, Bioanalytical Sciences, discusses assay categorization, the company's growing toolbox, predictions for the future, and more.

Released By Scorpius BioManufacturing

Sponsored Content

An Experienced CDMO Can Be A Differentiator In The Rapidly Growing Biologics Market

The demand for biologic drugs continues to grow at a steady 12–14% annually.

Released By Scorpius BioManufacturing

White Papers / Tech Papers

Report: Trends Shaping the Future of Emerging Biotechs

100 subject matter experts were surveyed from smaller biotech innovators to gain insight into the dynamics and drivers of the current biologics market.

Released By Scorpius BioManufacturing

Company Blog

What Does It Take To Be A Biologics CDMO That Can Serve Today’s Mammalian Clinical Mfg Needs?

Clinical manufacturing of cGMP-compliant mammalian cell culture processes is a complex and resource-intensive effort that presents several challenges.

Released By Scorpius BioManufacturing

Company Blog

Why Process Matters: How Biologics Process Development Can Accelerate Your Path To Market

Biologics process development is an active undertaking that seeks continuous improvement along the entire length of the drug development timeline.

Released By Scorpius BioManufacturing

Infographics

How a Biologics CDMO Adds Value to mAbs Development & Manufacturing Programs

A look at a CDMO’s value throughout a monoclonal antibody (mAb) therapeutic's lifecycle.

Released By Scorpius BioManufacturing

Company Blog

5 New Questions to Ask Before Signing with a Biologics CDMO

The value biologics CDMOs provide their innovator customers has changed radically in recent years, presenting new questions that must be answered.

Released By Scorpius BioManufacturing

Company Blog

Top 6 Questions To Ask When Evaluating A Biologics CDMO

The biologics CDMO selected for a given product or program is critical to an innovator’s ability to deliver a drug product safely, on time, and on budget.

Released By Scorpius BioManufacturing

Company Blog

How To Select The Right Biologics CDMO Partner

When selecting a biologics CDMO partner—whether you need mammalian or microbial capabilities—the decision-making process follows a similar process.

Released By Scorpius BioManufacturing

Case Studies

FinaBio’s Search for a CDMO to Support Affordable Conjugate Vaccines

Why Fina Biosolutions partnered with Scorpius Biomanufacturing for cGMP production of Ecocrm® (CRM197)

Released By Scorpius BioManufacturing

Company Blog

Evaluating Biologics CDMOs: Tips For Crafting An RFP

While crafting a RFP to capture the information innovators need to select a CDMO partner has always been critical; it has grown increasingly complicated.

Released By Scorpius BioManufacturing

News Releases

Fina Biosolutions Selects Scorpius BioManufacturing for Production of cGMP CRM197

The partnership includes recovery and downstream process optimization, analytical method implementation and phase-appropriate validation, and more.

Released By Scorpius BioManufacturing

Literature / Brochures

Scorpius’ cGMP Clinical Manufacturing Facility In San Antonio

Flexible, responsive, customized services for taking a program from R&D into the clinic, using American facilities and American sourced materials and equipment.

Released By Scorpius BioManufacturing

Literature / Brochures

Mammalian cGMP Manufacturing Capabilities at Scorpius

Delivering consistent and scalable mammalian-derived products, Scorpius uses its American facilities to advance your drug from R&D to the clinic and beyond.

Released By Scorpius BioManufacturing

Literature / Brochures

Microbial cGMP Manufacturing Capabilities at Scorpius

Scorpius’ team has extensive experience in E. coli microbial biomanufacturing, including hard-to-work-with inclusion bodies.

Released By Scorpius BioManufacturing

Literature / Brochures

Integrated Bioanalytical Capabilities at Scorpius

Utilizing American-made equipment and reagents, Scorpius develops custom assays to profile your molecule and test your clinical trial samples.

Released By Scorpius BioManufacturing

Literature / Brochures

Clinical Biomanufacturing Capabilities at Scorpius

Process development & cGMP contract manufacturing for biologics and cell therapies.

Released By Scorpius BioManufacturing

Related Content